Meeting
2013 ASCO Annual Meeting
Final results of a single-arm phase II study of bevacizumab and temozolomide following radiochemotherapy in newly dignosed adult glioblastoma patients.
Authors
Martin Kelly Nicholas
The University of Chicago, Chicago, IL
Martin Kelly Nicholas , Rimas Vincas Lukas , Christine Amidei , Nicholas Vick , Nina Paleologos , Mark Gordon Malkin , Hendrikus Krouwer , Larry Junck , Jean Arzbaecher , Albert Lai , Ryan Merrell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT005906
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2076)
DOI
10.1200/jco.2013.31.15_suppl.2076
Abstract #
2076
Poster Bd #
5H
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
First Author: A. M. P. Omuro
Poster
2014 ASCO Annual Meeting
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.
First Author: Ulrich Herrlinger
Poster
2014 ASCO Annual Meeting
Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma.
First Author: Abdullah Khalaf Altwairgi
Poster
2011 ASCO Annual Meeting
CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.
First Author: V. Verschaeve